Impact of omalizumab on treatment of severe allergic asthma in UK clinical practice: a UK multicentre observational study (the APEX II study).

Tools

Niven, Robert M, Saralaya, Dinesh, Chaudhuri, Rekha, Masoli, Matthew, Clifton, Ian, Mansur, Adel H, Hacking, Victoria, McLain-Smith, Susan and Menzies-Gow, Andrew (2016) Impact of omalizumab on treatment of severe allergic asthma in UK clinical practice: a UK multicentre observational study (the APEX II study). BMJ open, 6 (8). e011857. ISSN 2044-6055.

Preview

Text (PDF File)
Impact of omalizumab on treatment of severe allergic asthma in UK clinical practice a UK multicentre observational study the APEX II study.pdf - Published Version
Available under License Creative Commons Attribution Non-commercial.
Download (1MB) | Preview

Official URL: http://bmjopen.bmj.com/content/6/8/e011857.long

Abstract

OBJECTIVE

To describe the impact of omalizumab on asthma management in patients treated as part of normal clinical practice in the UK National Health Service (NHS).

DESIGN

A non-interventional, mixed methodology study, combining retrospective and prospective data collection for 12 months pre-omalizumab and post-omalizumab initiation, respectively.

SETTING

Data were collected in 22 UK NHS centres, including specialist centres and district general hospitals in the UK.

PARTICIPANTS

258 adult patients (aged ≥16 years; 65% women) with severe persistent allergic asthma treated with omalizumab were recruited, of whom 218 (84.5%) completed the study.

PRIMARY AND SECONDARY OUTCOME MEASURES

The primary outcome measure was change in mean daily dose of oral corticosteroids (OCS) between the 12-month pre-omalizumab and post-omalizumab initiation periods. A priori secondary outcome measures included response to treatment, changes in OCS dosing, asthma exacerbations, lung function, employment/education, patient-reported outcomes and hospital resource utilisation.

RESULTS

The response rate to omalizumab at 16 weeks was 82.4%. Comparing pre-omalizumab and post-omalizumab periods, the mean (95% CIs) daily dose of OCS decreased by 1.61 (-2.41 to -0.80) mg/patient/day (p<0.001) and hospital exacerbations decreased by 0.97 (-1.19 to -0.75) exacerbations/patient (p<0.001). Compared with baseline, lung function, assessed by percentage of forced expiratory volume in 1 s, improved by 4.5 (2.7 to 6.3)% at 16 weeks (p<0.001; maintained at 12 months) and patient quality of life (Asthma Quality of Life Questionnaire) improved by 1.38 (1.18 to 1.58) points at 16 weeks (p<0.001, maintained at 12 months). 21/162 patients with complete employment data gained employment and 6 patients lost employment in the 12-month post-omalizumab period. The mean number of A&E visits, inpatient hospitalisations, outpatient visits (excluding for omalizumab) and number of bed days/patient decreased significantly (p<0.001) in the 12-month post-omalizumab period.

CONCLUSIONS

These data support the beneficial effects of omalizumab on asthma-related outcomes, quality of life and resource utilisation in unselected patients treated in 'real-world' clinical practice.

Item Type:	Article
Subjects:	WF Respiratory system. Respiratory medicine
Divisions:	Planned IP Care > Respiratory Medicine
Related URLs:	https://www.ncbi.nlm.nih.gov/pmc/article...
Depositing User:	Mrs Adele Creak
Date Deposited:	03 Mar 2017 09:42
Last Modified:	03 Mar 2017 11:45
URI:	http://www.repository.uhblibrary.co.uk/id/eprint/1215

Actions (login required)

View Item